Interim Report January – September 2023
Business Highlights during the third quarter 2023
- Encouraging preclinical data using uTREAT® in non-small cell lung cancer
- Positive Phase II data reported from uTRACE® in brain cancer
- Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress
Copenhagen, Denmark, 23 November 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
“As we conclude the third quarter of 2023, I am delighted to share the latest progress and achievements at Curasight A/S. Building upon the strategic successes earlier this year, which included the signing of a partnership
with Curium, a global leader in the field of radio pharmaceuticals, we’ve continued to advance our position as a leading theranostic company, with Q3 marking yet another eventful period of growth and innovation.
Q3 2023 has been marked by significant achievements and promising developments that underscore our commitment to transforming the lives of cancer patients worldwide. One of the recent highlights was our announcement of positive preclinical data for our treatment platform, uTREAT®, in non-small cell lung cancer (NSCLC). These results provide strong support for uTREAT’s potential as a radioligand therapy, opening new avenues for treatment and further development in this indication.
Additionally, we were proud to share the positive outcomes from the investigator-initiated phase II study of our diagnosis platform uTRACE® in brain cancer, were the study highlighted that the majority of glioblastoma patients displayed uPAR-positive tumors, and high uPAR expression was significantly correlated with a worse outcome. This study supports our approach of using our uPAR theranostic platform in brain cancer, combining both diagnosis (uTRACE) with targeted radionuclide therapy in the form of uTREAT® for high grade gliomas.
Finally, as we look ahead to the remainder of this year and into 2024, we expect further progress in our pipeline. We anticipate the announcements of additional results from preclinical studies in various cancer types with uTREAT® as well as filing applications to authorities in the EU and US to start new clinical studies with both uTRACE® and uTREAT®. Advancing these clinical trials will be crucial steps in our pursuit of making our innovative solutions accessible to cancer patients on a global scale.”
Q3 (2023-07-01 – 2023-09-30)
- Net sales amounted to 0 (0) kDKK
- Gross profit/loss amounted to -6 551 (-416) kDKK
- Profit/loss before taxes amounted to -8 484 (-3 861) kDKK
- Profit/loss for the period amounted to -6 618 (-3 805) kDKK
- Total assets amounted to 41 913 (68 892) kDKK
- Equity ratio amounted to 90.2 (94.8) %
- Earnings per share amounted to -0.33 (-0.19) DKK
Q1 – Q3 (2023-01-01 – 2023-09-30)
- Net sales amounted to 0 (0) kDKK
- Gross profit/loss amounted to -20 236 (-6 131) kDKK
- Profit/loss before taxes amounted to -25 328 (-12 601) kDKK
- Profit/loss for the period amounted to -19 756 (-10 622) kDKK
- Total assets amounted to 41 913 (68 892) kDKK
- Equity ratio amounted to 90.2 (94.8) %.
- Earnings per share amounted to -0.99 (-0.53) DKK
